The 40th JPM 2022 Healthcare Conference was held from January 10th to 13th, with digital meetings continuing until the end of January, enabling exchanges among 制药公司 from around the world.
This meeting brought together a large number of domestic 制药 and bio companies, including 三星生物制品, making it an occasion to discuss global 技术转让s.
With many domestic companies participating in the main track, emerging track, and Asia-Pacific sessions, RudaCure was also able to continue discussions on RCI001 and RCI002 with interested parties including Kintor, Qilu, Alimera Sciences, and AbbVie through this JPM conference.
Among these, AbbVie expressed significant interest in RCI001, showing great enthusiasm for the 临床试验 progress and expressing amazement at the drug's 疗效 through its novel 作用机制, hoping to establish an ongoing relationship. Chinese companies were also able to exchange information about market conditions in 中国.